These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 27881132)

  • 1. Integrated safety and efficacy analysis of once-daily fluticasone furoate for the treatment of asthma.
    O'Byrne PM; Jacques L; Goldfrad C; Kwon N; Perrio M; Yates LJ; Busse WW
    Respir Res; 2016 Nov; 17(1):157. PubMed ID: 27881132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety profile of fluticasone furoate administered once daily in the morning or evening: a randomized, double-blind, double-dummy, placebo-controlled trial in adult and adolescent patients with persistent bronchial asthma.
    Medley H; Orozco S; Allen A
    Clin Ther; 2012 Aug; 34(8):1683-95. PubMed ID: 22796247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose effect of once-daily fluticasone furoate in persistent asthma: a randomized trial.
    Bateman ED; Bleecker ER; Lötvall J; Woodcock A; Forth R; Medley H; Davis AM; Jacques L; Haumann B; Busse WW
    Respir Med; 2012 May; 106(5):642-50. PubMed ID: 22342538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ethnic sensitivity assessment of fluticasone furoate/vilanterol in East Asian asthma patients from randomized double-blind multicentre Phase IIb/III trials.
    Gross AS; Goldfrad C; Hozawa S; James MH; Clifton CS; Sugiyama Y; Jacques L
    BMC Pulm Med; 2015 Dec; 15():165. PubMed ID: 26704701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthma.
    Woodcock A; Bleecker ER; Busse WW; Lötvall J; Snowise NG; Frith L; Jacques L; Haumann B; Bateman ED
    Respir Res; 2011 Dec; 12(1):160. PubMed ID: 22188590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
    Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
    Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of fluticasone furoate 100 μg and 200 μg once daily in the treatment of moderate-severe asthma in adults and adolescents: a 24-week randomised study.
    Woodcock A; Lötvall J; Busse WW; Bateman ED; Stone S; Ellsworth A; Jacques L
    BMC Pulm Med; 2014 Jul; 14():113. PubMed ID: 25007865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and Systemic Activity of a New Patent of an Inhaled Corticosteroid/Long-Acting β2-Agonist Combination for Use in Asthma Therapy: Fluticasone Furoate/Vilanterol Trifenatate.
    Wolthers OD
    Recent Pat Inflamm Allergy Drug Discov; 2015; 9(2):144-50. PubMed ID: 26581314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Once-daily fluticasone furoate 50 mcg in mild-to-moderate asthma: a 24-week placebo-controlled randomized trial.
    Busse WW; Bateman ED; O'Byrne PM; Lötvall J; Woodcock A; Medley H; Forth R; Jacques L
    Allergy; 2014 Nov; 69(11):1522-30. PubMed ID: 25040613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhaled fluticasone furoate/vilanterol does not affect hypothalamic-pituitary-adrenal axis function in adolescent and adult asthma: randomised, double-blind, placebo-controlled study.
    Allen A; Schenkenberger I; Trivedi R; Cole J; Hicks W; Gul N; Jacques L
    Clin Respir J; 2013 Oct; 7(4):397-406. PubMed ID: 23578031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Once-daily fluticasone furoate is efficacious in patients with symptomatic asthma on low-dose inhaled corticosteroids.
    Bleecker ER; Bateman ED; Busse WW; Woodcock A; Frith L; House KW; Jacques L; Davis AM; Haumann B; Lötvall J
    Ann Allergy Asthma Immunol; 2012 Nov; 109(5):353-358.e4. PubMed ID: 23062392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Once-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone.
    Bateman ED; O'Byrne PM; Busse WW; Lötvall J; Bleecker ER; Andersen L; Jacques L; Frith L; Lim J; Woodcock A
    Thorax; 2014 Apr; 69(4):312-9. PubMed ID: 24253831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of fluticasone furoate 100 μg once-daily in patients with persistent asthma: a 24-week placebo and active-controlled randomised trial.
    Lötvall J; Bleecker ER; Busse WW; O'Byrne PM; Woodcock A; Kerwin EM; Stone S; Forth R; Jacques L; Bateman ED
    Respir Med; 2014 Jan; 108(1):41-9. PubMed ID: 24295556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Once-daily fluticasone furoate and vilanterol for adolescents and adults with symptomatic asthma: A systematic review with meta-analysis.
    Rodrigo GJ; Plaza V
    Ann Allergy Asthma Immunol; 2016 Jun; 116(6):565-70. PubMed ID: 27117053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomised trial of once-daily vilanterol in children with asthma on inhaled corticosteroid therapy.
    Oliver AJ; Covar RA; Goldfrad CH; Klein RM; Pedersen SE; Sorkness CA; Tomkins SA; Villarán C; Grigg J
    Respir Res; 2016 Apr; 17():37. PubMed ID: 27044326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events.
    Cates CJ; Lasserson TJ
    Cochrane Database Syst Rev; 2010 Jan; (1):CD007694. PubMed ID: 20091646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of once-daily fluticasone furoate 50 mcg in adults with persistent asthma: a 12-week randomized trial.
    O'Byrne PM; Woodcock A; Bleecker ER; Bateman ED; Lötvall J; Forth R; Medley H; Jacques L; Busse WW
    Respir Res; 2014 Aug; 15(1):88. PubMed ID: 25108545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials.
    Dransfield MT; Bourbeau J; Jones PW; Hanania NA; Mahler DA; Vestbo J; Wachtel A; Martinez FJ; Barnhart F; Sanford L; Lettis S; Crim C; Calverley PM
    Lancet Respir Med; 2013 May; 1(3):210-23. PubMed ID: 24429127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relationship between fluticasone furoate systemic exposure and cortisol suppression.
    Allen A
    Clin Pharmacokinet; 2013 Oct; 52(10):885-96. PubMed ID: 23719680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial.
    Busse WW; Bleecker ER; Bateman ED; Lötvall J; Forth R; Davis AM; Jacques L; Haumann B; Woodcock A
    Thorax; 2012 Jan; 67(1):35-41. PubMed ID: 21828231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.